Prognostic Factors Predicting Remission Following Rituximab Therapy for Pemphigus Vulgaris
DOI:
https://doi.org/10.2340/actadv.v105.27140Keywords:
pemphigus vulgaris, prognosis, prognostic factors, rituximabAbstract
Pemphigus vulgaris is a chronic autoimmune blistering disease with significant morbidity. Rituximab, approved as its first-line treatment, effectively induces remission. However, few studies have analysed the prognostic factors for improved rituximab outcomes. Therefore, this study aimed to identify such factors in a cohort of pemphigus vulgaris patients. A total of 142 pemphigus vulgaris patients treated with rituximab at Sheba Medical Center, with data encompassing demographics, comorbidities, disease characteristics, and treatment outcomes, were retrospectively examined. Results showed that 61.9% of patients previously treated with mycophenolate mofetil achieved partial remission, whereas only 34.7% achieved complete remission. Patients with diabetes mellitus exhibited a significantly shorter median time to relapse compared with those without. Patients with a disease duration ≤ 16 months before rituximab therapy exhibited a shorter median time to relapse. Moreover, previous dapsone treatment extended time to relapse. Notably, sex, age at symptom onset and rituximab therapy, ethnicity, comorbidities, skin involvement, weight, rituximab dosing protocol, and other variables were not statistically significant between the complete remission and partial remission groups. These findings highlight the influence of specific patient characteristics and treatment histories on response to rituximab and time to relapse in pemphigus vulgaris patients. Understanding these factors can aid clinicians in predicting treatment outcomes and selecting the appropriate patient population for rituximab therapy.
Downloads
References
Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet 2019; 394: 882–894.
https://doi.org/10.1016/S0140-6736(19)31778-7 DOI: https://doi.org/10.1016/S0140-6736(19)31778-7
Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS, et al. Pemphigus. Nat Rev Dis Primer 2017; 3: 17026.
https://doi.org/10.1038/nrdp.2017.26 DOI: https://doi.org/10.1038/nrdp.2017.26
Harman KE, Brown D, Exton LS, Groves RW, Hampton PJ, Mohd Mustapa MF, et al. British Association of Dermatologists’ guide-lines for the management of pemphigus vulgaris 2017. Br J Dermatol 2017; 177: 1170–1201.
https://doi.org/10.1111/bjd.15930 DOI: https://doi.org/10.1111/bjd.15930
Frampton JE. Rituximab: a review in pemphigus vulgaris. Am J Clin Dermatol 2020; 21: 149–156.
https://doi.org/10.1007/s40257-019-00497-9 DOI: https://doi.org/10.1007/s40257-019-00497-9
Ahmed AR, Shetty S. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with ritux-imab. Autoimmun Rev 2015; 14: 323–331.
https://doi.org/10.1016/j.autrev.2014.12.002 DOI: https://doi.org/10.1016/j.autrev.2014.12.002
Nosrati A, Hodak E, Mimouni T, Oren-Shabtai M, Levi A, Leshem YA, et al. Treatment of pemphigus with rituximab: real-life expe-rience in a cohort of 117 patients in Israel. Dermatol Basel Switz 2021; 237: 450–456.
https://doi.org/10.1159/000513515 DOI: https://doi.org/10.1159/000513515
Sharma VK, Gupta V, Bhari N, Singh V. Rituximab as an adjuvant therapy for pemphigus: experience in 61 patients from a single center with long-term follow-up. Int J Dermatol 2020; 59: 76–81.
https://doi.org/10.1111/ijd.14546 DOI: https://doi.org/10.1111/ijd.14546
Baum S, Raviv T, Gilboa S, Pavlotsky F, Barzilai A. Efficacy of repeated courses of rituximab as treatment for pemphigus vulgaris. Acta Derm Venereol 2020; 100: adv00286.
https://doi.org/10.2340/00015555-3649 DOI: https://doi.org/10.2340/00015555-3649
Kushner CJ, Wang S, Tovanabutra N, Tsai DE, Werth VP, Payne AS. Factors associated with complete remission after rituximab therapy for pemphigus. JAMA Dermatol 2019; 155: 1404–1409.
https://doi.org/10.1001/jamadermatol.2019.3236 DOI: https://doi.org/10.1001/jamadermatol.2019.3236
Saha M, Bhogal B, Black MM, Cooper D, Vaughan RW, Groves RW. Prognostic factors in pemphigus vulgaris and pemphigus folia-ceus. Br J Dermatol 2014; 170: 116–122.
https://doi.org/10.1111/bjd.12630 DOI: https://doi.org/10.1111/bjd.12630
Loi C, Magnano M, Ravaioli GM, Sacchelli L, Patrizi A, Bardazzi F. Rituximab therapy in pemphigus: a long-term follow-up. Dermatol Ther 2019; 32: e12763.
https://doi.org/10.1111/dth.12763 DOI: https://doi.org/10.1111/dth.12763
Kim TH, Choi Y, Lee SE, Lim JM, Kim SC. Adjuvant rituximab treatment for pemphigus: a retrospective study of 45 patients at a single center with long-term follow up. J Dermatol 2017; 44: 615–620.
https://doi.org/10.1111/1346-8138.13757 DOI: https://doi.org/10.1111/1346-8138.13757
Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, et al. Adjuvant rituximab therapy of pemphigus: a single-center expe-rience with 31 patients. Arch Dermatol 2012; 148: 1031–1036.
https://doi.org/10.1001/archdermatol.2012.1522 DOI: https://doi.org/10.1001/archdermatol.2012.1522
Cho SI, Kim JW, Lim JS, Chung JH. Mucosal involvement is a risk factor for poor clinical outcomes and relapse in patients with pemphigus treated with rituximab. Dermatol Ther 2019; 32: e12814.
https://doi.org/10.1111/dth.12814 DOI: https://doi.org/10.1111/dth.12814
Ran NA, Payne AS. Rituximab therapy in pemphigus and other autoantibody-mediated diseases. F1000Research 2017; 6: 83.
https://doi.org/10.12688/f1000research.9476.1 DOI: https://doi.org/10.12688/f1000research.9476.1
Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, et al. Updated consensus statement on the use of ritux-imab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 909–920.
https://doi.org/10.1136/ard.2010.144998 DOI: https://doi.org/10.1136/ard.2010.144998
Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043–1046.
https://doi.org/10.1016/j.jaad.2008.01.012 DOI: https://doi.org/10.1016/j.jaad.2008.01.012
Parameswaran A, Attwood K, Sato R, Seiffert-Sinha K, Sinha AA. Identification of a new disease cluster of pemphigus vulgaris with autoimmune thyroid disease, rheumatoid arthritis and type I diabetes. Br J Dermatol 2015; 172: 729–738.
https://doi.org/10.1111/bjd.13433 DOI: https://doi.org/10.1111/bjd.13433
Sánchez-García V, Pérez-Alcaraz L, Belinchón-Romero I, Ramos-Rincón JM. Comorbidities in patients with autoimmune bullous disorders: hospital-based registry study. Life 2022; 12: 595.
https://doi.org/10.3390/life12040595 DOI: https://doi.org/10.3390/life12040595
Amber KT, Hertl M. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. J Eur Acad Dermatol Venereol 2015; 29: 777–782.
https://doi.org/10.1111/jdv.12678 DOI: https://doi.org/10.1111/jdv.12678
Nosrati A, Mimouni T, Hodak E, Gdalevich M, Oren-Shabtai M, Levi A, et al. Early rituximab treatment is associated with increased and sustained remission in pemphigus patients: a retrospective cohort of 99 patients. Dermatol Ther 2022; 35: e15397.
https://doi.org/10.1111/dth.15397 DOI: https://doi.org/10.1111/dth.15397
Balighi K, Daneshpazhooh M, Akbari Z, Tavakolpour S, Azimi P, Azizpour A. Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months. J Dermatol Treat 2019; 30: 346–349.
https://doi.org/10.1080/09546634.2018.1509049 DOI: https://doi.org/10.1080/09546634.2018.1509049
Balighi K, Daneshpazhooh M, Mahmoudi H, Badakhsh M, Teimourpour A, Ehsani AH, et al. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better? Arch Dermatol Res 2019; 311: 63–69.
https://doi.org/10.1007/s00403-018-1881-1 DOI: https://doi.org/10.1007/s00403-018-1881-1
Anandan V, Jameela WA, Sowmiya R, Kumar MMS, Lavanya P. Rituximab: a magic bullet for pemphigus. J Clin Diagn Res JCDR 2017; 11: WC01–WC06.
https://doi.org/10.7860/JCDR/2017/21868.9717 DOI: https://doi.org/10.7860/JCDR/2017/21868.9717
Kyriakis KP, Tosca AD. Epidemiologic observations on the natural course of pemphigus vulgaris. Int J Dermatol 1998; 37: 215–219.
https://doi.org/10.1046/j.1365-4362.1998.00317.x DOI: https://doi.org/10.1046/j.1365-4362.1998.00317.x
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet Lond Engl 2017; 389: 2031–2040.
https://doi.org/10.1016/S0140-6736(17)30070-3 DOI: https://doi.org/10.1016/S0140-6736(17)30070-3
Mignard C, Maho-Vaillant M, Golinski ML, Balayé P, Prost-Squarcioni C, Houivet E, et al. Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial. JAMA Dermatol 2020; 156: 545–552.
https://doi.org/10.1001/jamadermatol.2020.0290 DOI: https://doi.org/10.1001/jamadermatol.2020.0290
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Tal Raviv, Keren Pevzner, Aviv Barzilai, Felix Pavlotsky, Sharon Baum
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
